Trials / Completed
CompletedNCT05178888
Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
A Phase 1/1b Trial of MRTX849 in Combination With Palbociclib in Patients With Advanced Solid Tumors With KRAS G12C Mutation
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Mirati Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and clinical activity of MRTX849 (adagrasib) in combination with palbociclib in patients with advanced solid tumor malignancies with KRAS G12C mutation.
Detailed description
This study will evaluate the pharmacokinetics and preliminary clinical activity of MRTX849 (adagrasib) in combination with palbociclib in patients with advanced solid tumor malignancies with KRAS G12C mutation. MRTX849 is an orally available small molecule inhibitor of KRAS G12C and palbociclib is a small molecule inhibitor of CDK 4 and 6.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRTX849 | KRAS G12C inhibitor |
| DRUG | Palbociclib | CDK 4 and 6 inhibitor |
Timeline
- Start date
- 2022-01-20
- Primary completion
- 2023-06-15
- Completion
- 2024-12-30
- First posted
- 2022-01-05
- Last updated
- 2025-02-11
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05178888. Inclusion in this directory is not an endorsement.